India Rolls Out Modicare - Can It Redefine Healthcare Access, Market Potential?
India has rolled out its massive government-funded health care program, expanding access to treatment to more than 100 million families. Though ambitious and complex and a scheme that could face intense scrutiny in the run up to general elections next year, the sheer scale of the initiative may also throw up significant market expansion or partnering opportunities for hospitals and pharma.
You may also be interested in...
India’s government has hiked healthcare spending in its new budget by 13.5% ahead of national elections, earmarking the lion’s share for its flagship new health insurance scheme for the nation’s poorest half-billion people. But outlays for the stretched core public health-delivery system have stagnated.
Paul Hudson, CEO, Novartis Pharmaceuticals, was recently in India along with the executive leadership team of the Swiss multinational. In a wide-ranging exclusive interview with Scrip, he discussed Cosentyx’s edge over its competition, Entresto’s “incredibly bright future”, including in emerging markets like India, and why transparency on the scale of rebates in the US is "overdue."
Lara Bezerra, Roche’s new managing director in India, outlines in an interview with Scrip how the Swiss multinational is now looking at the Indian market through a different lens and beyond short-term gains.